Semaglutide
Semaglutide
Semaglutide is a synthetic peptide studied in in-vitro and preclinical research as a GLP-1 receptor agonist. Research reagent only — not for human consumption or medical use.
Key facts
- Class
- GLP-1 agonist
- Target
- GLP-1 receptor
- Form
- Lyophilised (powder)
- Status
- Research Use Only
Study library
All results on PubMedSafety of Semaglutide.
Smits MM, et al. · Frontiers in endocrinology · 2021
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Davies M, et al. · Lancet (London, England) · 2021
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery S, et al. · JCI insight · 2020
Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
Tan HC, et al. · Journal of the ASEAN Federation of Endocrine Societies · 2022
Clinical Pharmacokinetics of Semaglutide: A Systematic Review.
Yang XD, et al. · Drug design, development and therapy · 2024
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.
Hathaway JT, et al. · JAMA ophthalmology · 2024
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Pratley RE, et al. · The lancet. Diabetes & endocrinology · 2018
Semaglutide: First Global Approval.
Dhillon S · Drugs · 2018
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Sorli C, et al. · The lancet. Diabetes & endocrinology · 2017
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
Kadowaki T, et al. · The lancet. Diabetes & endocrinology · 2022
Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated mitochondrial dysfunction.
Li X, et al. · Redox biology · 2024
Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
Blundell J, et al. · Diabetes, obesity & metabolism · 2017
Results retrieved live from PubMed (NCBI). Research literature only — no medical advice.
Research peptides — Research Use Only
- Not for human consumption
- Not for the diagnosis, treatment or prevention of any disease